A complex cytokine influence at the maternal-fetal interface creates the conditions that are necessary to support embryo implantation in the endometrium [92, 93]
The Lancet Haematology, 6 (6), e317e327
She takes them with a camera often last used in the 1990s
- (+)-catechin hydrate - inhibition of isozymes GST M1-1 and M2-2 (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol - a coumaroflavan from Treculia africana, 26% total inhibition at 0.033 mM (2Z)-2-[(4-methoxyphenyl)carbonyl]-3-(2,3,4-trimethoxyphenyl)prop-2-enoic acid - - (2Z)-2-[(4-methylphenyl)carbonyl]-3-(2,3,4-trimethoxyphenyl)prop-2-enoic acid - - (2Z)-2-[(4-methylphenyl)carbonyl]-3-phenylprop-2-enoic acid - 8.1% inhibition at 0.02 mM (2Z)-3-(1,3-benzodioxol-5-yl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid - 10% inhibition at 0.02 mM (2Z)-3-(1,3-benzodioxol-5-yl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 9.6% inhibition at 0.02 mM (2Z)-3-(2-methylphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 9.3% inhibition at 0.02 mM (2Z)-3-(3,4-dihydroxyphenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid - - (2Z)-3-(3,4-dihydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - - (2Z)-3-(3-hydroxyphenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid - 6.6% inhibition at 0.02 mM (2Z)-3-(3-hydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 13.9% inhibition at 0.02 mM (2Z)-3-(3-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 19.0% inhibition at 0.02 mM (2Z)-3-(4-chlorophenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid - 14.4% inhibition at 0.02 mM (2Z)-3-(4-chlorophenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 14.4% inhibition at 0.02 mM (2Z)-3-(4-fluorophenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - - (2Z)-3-(4-hydroxy-3-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 8.8% inhibition at 0.02 mM (2Z)-3-(4-hydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 12.5% inhibition at 0.02 mM (2Z)-3-(4-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - - (2Z)-3-(4-methylphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - - (2Z)-3-[4-(dimethylamino)phenyl]-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid - 9.3% inhibition at 0.02 mM (4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)methanesulfonyl fluoride - - (4S,6Z,10Z,11aS)-4-ethoxy-6-(hydroxymethyl)-3-methylidene-10-propoxy-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one - a sesquiterpene lactone from Dicoma anomala collected from Namibia, 75% total inhibition at 0.033 mM (E)-2-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)ethene-1-sulfonyl fluoride - - (E)-N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)but-2-enamide - - 1,4-pentadiene-3-one - curcumin derivative 1,7-dihydroxyanthracen-9(10H)-one - a xanthone from Mammea africana, 21% total inhibition at 0.033 mM 1-(4-benzylpiperidin-1-yl)prop-2-en-1-one - 1-(4-phenylpiperidin-1-yl)prop-2-en-1-one - 1-chloro-2,4-dinitrobenzene - competitive inhibition by the substrate 1-methyl-2-[((2-nitrobenzyl)sulfonyl)]-1H-pyrrole - 44.3% inhibition at 0.1 mM 1-methyl-2-[(2-nitrobenzyl)sulfanyl]-1H-pyrrole - - 2,5-dibenzylidenecyclopentanone - curcumin derivative 2,6-dibenzylidenecyclohexanone - curcumin derivative 2-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)ethane-1-sulfonyl fluoride - - 2-(4-chlorophenyl)-6-[(fluorosulfonyl)oxy]quinoline-4-carboxylic acid - 2-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)imidazole - - 2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-((1E)-[4-(trifluoromethyl)phenyl]methylene)aniline - 68.4% inhibition at 0.1 mM 2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-(4-nitrophenyl)methylene]aniline - 90.0% inhibition at 0.1 mM 2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-(phenyl)methylene]aniline - 30.2% inhibition at 0.1 mM 2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-1H-pyrrol-2-ylmethylene]aniline - 36.0% inhibition at 0.1 mM 2-chloro-5-((cyanomethyl)amino)-N,N-dimethylbenzenesulfonamide - - 2-chloro-N,N-dimethyl-5 -(oxiran-2-ylmethyl) -benzenesulfonamide - - 2-chloro-N,N-dimethyl-5-(oxiran-2-yl)benzenesulfonamide - - 2-chloro-N,N-dimethyl-5-(vinylsulfonamido)-benzenesulfonamide - 2-chloro-N-(2-(N,N-dimethylsulfamoyl)-[1,1'-biphenyl]-4-yl)-acetamide - - 2-chloro-N-(3-(morpholinosulfonyl)-4-(trifluoromethyl)phenyl)-acetamide - - 2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-(trifluoromethoxy)-phenyl)acetamide - - 2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-(trifluoromethyl)-phenyl)acetamide - - 2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-iodophenyl)-acetamide - - 2-chloro-N-(4-(2-hydroxyphenyl)thiazol-2-yl)-N-((3-methylisoxazol-5-yl)methyl)acetamide - 2-chloro-N-(4-chloro-3-(morpholinosulfonyl)phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-propanamide - - 2-chloro-N-(4-chloro-3-(N-((tetrahydrofuran-2-yl)methyl)-sulfamoyl)phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N-(2-hydroxyethyl)-N-methylsulfamoyl)phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N-(2-hydroxyethyl)sulfamoyl)phenyl)-acetamide - - 2-chloro-N-(4-chloro-3-(N-(2-methoxyethyl)-N-methylsulfamoyl)phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N-(2-methoxyethyl)sulfamoyl)phenyl)-acetamide - - 2-chloro-N-(4-chloro-3-(N-(3-methoxypropyl)-N-methylsulfamoyl)phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N-(3-methoxypropyl)sulfamoyl)phenyl)-acetamide - - 2-chloro-N-(4-chloro-3-(N-(tetrahydrofuran-3-yl)sulfamoyl)-phenyl)acetamide - - 2-chloro-N-(4-chloro-3-(N-isopropylsulfamoyl)phenyl)-acetamide - - 2-chloro-N-(4-chloro-3-(N-methylsulfamoyl)phenyl)acetamide - - 2-chloro-N-methyl-N-[(1-phenyl-1H-pyrazol-3-yl)methyl]acetamide i.e
Symptoms that do not improve with over-the-counter treatments
- C.
